Table II.

Survival estimates and risk of death by tumor thickness, ulceration, nodal involvement, and stage of non-Hispanic white patients with melanoma from the California Cancer Registry (2004–2013)

Survival estimate
Tumor classification			12 mo			24 mo			36 mo			60 mo
Characteristic	n	%	Survival estimate	95% CI		Survival estimate	95% CI		Survival estimate	95% CI		Survival estimate	95% CI
<0.8 mm	28,110	87.9	98.1%	97.9%	98.2%	95.9%	95.6%	96.1%	93.7%	93.4%	94.0%	89.0%	88.5%	89.4%
0.8-1.0 mm	3855	12.1	97.5%	96.9%	98.0%	94.6%	93.8%	95.3%	91.6%	90.6%	92.5%	86.3%	84.9%	87.6%
≤1.0	31,965	74.3	98.0%	97.8%	98.1%	95.7%	95.4%	95.9%	93.4%	93.1%	93.7%	88.6%	88.2%	89.0%
Nonulcerated	30,873	71.8	98.2%	98.0%	98.3%	96.1%	95.8%	96.3%	93.9%	93.6%	94.2%	89.1%	88.6%	89.5%
Without nodal involvement	29,877	69.5	98.3%	98.1%	98.4%	96.2%	96.0%	96.5%	94.1%	93.8%	94.4%	89.3%	88.9%	89.8%
With nodal involvement	297	0.7	91.5%	87.5%	94.3%	80.6%	75.0%	85.0%	73.7%	67.4%	79.0%	66.7%	59.6%	72.9%
With unknown nodal involvement	699	1.6	97.4%	95.9%	98.4%	94.9%	92.9%	96.4%	92.4%	89.9%	94.3%	87.6%	83.9%	90.5%
Ulcerated	1092	2.5	92.5%	90.6%	93.9%	85.2%	82.8%	87.4%	81.7%	78.9%	84.1%	75.5%	72.1%	78.5%
Without nodal involvement	960	2.2	94.1%	92.3%	95.5%	88.7%	86.3%	90.7%	85.3%	82.6%	87.7%	78.8%	75.4%	81.8%
With nodal involvement	111	0.3	79.8%	70.6%	86.3%	57.9%	46.8%	67.5%	50.8%	39.1%	61.3%	—	—	—
Staged tumors
Stage IIA	3347	7.8	94.5%	93.7%	95.3%	87.8%	86.5%	88.9%	80.3%	78.8%	81.8%	69.5%	67.5%	71.4%
Stage IIB	2350	5.5	92.7%	91.5%	93.7%	81.8%	80.0%	83.4%	72.2%	70.0%	74.2%	58.6%	56.0%	61.1%
Stage III	3137	7.3	89.6%	88.4%	90.6%	74.3%	72.6%	76.0%	64.3%	62.4%	66.2%	53.9%	51.7%	56.0%
Stage IV	2209	5.1	39.1%	37.0%	41.2%	25.5%	23.5%	27.5%	19.1%	17.3%	21.0%	14.9%	13.1%	16.8%
All-cause and melanoma-specific risk of death
Tumor characteristics			All-cause risk of death						Melanoma-specific risk of death
	n	%	HRc	95% CI		HRa	95% CI		HRc	95% CI		HRa	95% CI
<1 mm, not ulcerated	30,872	71.6	1.00			1.00			1.00			1.00
<1 mm, ulcerated	1092	2.5	2.54	2.22	2.92	2.27	1.97	2.61	7.89	6.23	10.0	7.45	5.84	9.51
Stage IIA	3446	8.0	3.00	2.78	3.24	2.46	2.26	2.66	7.06	6.00	8.31	6.67	5.64	7.88
Stage IIB	2350	5.5	4.38	4.05	4.75	3.31	3.04	3.60	13.14	11.25	15.34	11.56	9.83	13.59
Stage III	3137	7.3	5.17	4.82	5.54	5.31	4.93	5.72	27.23	24.00	30.90	26.52	23.23	30.29
Stage IV	2207	5.1	25.43	23.89	27.06	22.36	20.89	23.94	127.07	112.50	143.52	113.53	99.65	129.34
Thin melanomas
	n	%	HRc	95% CI		HRa	95% CI		HRc	95% CI		HRa	95% CI
<1 mm, not ulcerated
Without nodal invasion	29,876	93.5	1.00			1.00			1.00			1.00
With nodal invasion	297	0.9	3.67	2.92	4.62	4.55	3.60	5.76	20.33	14.90	27.75	19.83	14.24	27.60
With unknown nodal invasion	699	2.2	1.25	0.98	1.59	1.14	0.89	1.46	1.79	0.98	3.26	1.72	0.91	3.24
<1 mm, ulcerated
Without nodal invasion	960	3.0	2.19	1.87	2.56	1.88	1.60	2.20	6.82	5.13	9.06	6.14	4.58	8.23
With nodal invasion	111	0.3	9.04	6.71	12.19	10.07	7.33	13.83	43.62	28.72	66.25	45.64	29.22	71.30
With unknown nodal invasion	21	0.1	5.32	2.53	11.17	6.76	3.22	14.23	27.92	10.41	74.91	32.07	11.90	86.39

Cl, Confidence interval; HRa,fully adjusted hazard ratio (adjusted for sex. age at diagnosis, socioeconomic status, histology, chemotherapy, immunotherapy, sentinel lymph node biopsy,and year of diagnosis; HRc, crude hazard ratio